A case of juvenile acromegaly that was initially diagnosed as severe congestive heart failure from acromegaly-induced dilated cardiomyopathy

Internal Medicine

Volumn 49, Issue 19, 2010, Pages 2117-2121

  Sue, Mariko ^a   Yoshihara, Aya ^a   Okubo, Yoichiro ^a   Ishikawa, Mayumi ^a   Ando, Yasuyo ^a   Hiroi, Naoki ^a   Shibuya, Kazutoshi ^a   Yoshino, Gen ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acromegalic cardiomyopathy; Acromegaly; Dilated cardiomyopathy

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROMOCRIPTINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C; VASODILATOR AGENT;

ACROMEGALY; ADULT; ARTICLE; BODY MASS; CARDIOMEGALY; CASE REPORT; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; DEATH; DYSPNEA; FATIGUE; GROWTH HORMONE BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; LEG EDEMA; MALE; MITRAL VALVE REGURGITATION; NUCLEAR MAGNETIC RESONANCE IMAGING; THORAX PAIN; THORAX RADIOGRAPHY; TRANSSPHENOIDAL HYPOPHYSECTOMY; TRANSTHORACIC ECHOCARDIOGRAPHY; TRICUSPID VALVE REGURGITATION;

ACROMEGALY; CARDIOMYOPATHY, DILATED; DIAGNOSIS, DIFFERENTIAL; FATAL OUTCOME; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HEART FAILURE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MAGNETIC RESONANCE IMAGING; MALE; YOUNG ADULT;

EID: 77958101518     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.3972     Document Type: Article

References (27)

1. Gómez-Barrado JJ, Turégano S, Marcos G, Porras Y. Dilated cardiomyopathy in a patient with acromegaly: echocardiographic development after treatment. Rev Esp Cardiol 60: 213-214, 2007 (in Spanish).
2. Melmed S. Acromegaly. N Engl J Med 2: 966-977, 1990.
3. Clayton RN. Cardiovascular function in acromegaly. Endocr Rev 24: 272-277, 2003.
4. Scacchi M, Cavagnini F. Acromegaly. Pituitary 9: 297-303, 2006.
5. Bihan H, Espinosa C, Valdes-Socin H, et al. Long-term outcome of patients with acromegaly and congestive heart failure. J Clin Endocrinol Metab 89: 5308-5313, 2004.
6. Vitale G, Pivonello R, Lombardi G, Colao A. Cardiac abnormalities in acromegaly. Pathophysiology and implications for management. Treat Endocrinol 3: 309-318, 2004.
7. Lombardi G, Galdiero M, Auriemma RS, Pivonello R, Colao A. Acromegaly and the cardiovascular system. Neuroendocrinology 83: 211-217, 2006.
8. Colao A, Marzullo P, Di Somma C, Lombardi G. Growth hormone and the heart. Clin Endocrinol (Oxf) 54: 137-154, 2001.
9. Matta MP, Caron P. Acromegalic cardiomyopathy: a review of the literature. Pituitary 6: 203-207, 2003.
10. Colao A, Spinelli L, Cuocolo A, et al. Cardiovascular consequences of early-onset growth hormone excess. J Clin Endocrinol Metab 87: 3097-3104, 2002.
11. de Leeuw N, Ruiter DJ, Balk AH, de Jonge N, Melchers WJ, Galama JM. Histopathologic findings in explanted heart tissue from patients with end-stage idiopathic dilated cardiomyopathy. Transpl Int 14: 299-306, 2001.
12. Kimura A. Molecular etiology and pathogenesis of hereditary cardiomyopathy. Circ J 72(Suppl A): A38-A48, 2008.
13. Knoll R, Hoshijima M, Hoffman HM, et al. The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. Cell 111: 943-955, 2002.
14. Saccá L, Napoli R, Cittadini A. Growth hormone, acromegaly, and heart failure: an intricate triangulation. Clin Endocrinol (Oxf) 59: 660-671, 2003.
15. Movahed MR, Saito Y. Obesity is associated with left atrial enlargement, E/A reversal and left ventricular hypertrophy. Exp Clin Cardiol 13: 89-91, 2008.
16. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 347: 305-313, 2002.
17. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 161: 996-1002, 2001.
18. Jessup M, Brozena S. Heart failure. N Engl J Med 348: 2007-2018, 2003.
19. Mukherjee A, Murray RD, Shalet SM. Impact of growth hormone status on body composition and the skeleton. Horm Res 62(Suppl 3): 35-41, 2004.
20. Kaji H, Sugimoto T, Nakaoka D, et al. Bone metabolism and body composition in Japanese patients with active acromegaly. Clin Endocrinol (Oxf) 55: 175081, 2001.
21. Schmid C, Goede DL, Hauser RS, Brändle M. Increased prevalence of high body mass index in patients presenting with pituitary tumors: severe obesity in patients with macroprolactinioma. Swiss Med Wkly 136: 254-258, 2006.
22. Colao A, Vitale G, Pivonello R, Ciccarelli A, Di Somma C, Lombardi G. The heart: an end-organ of GH action. Eur J Endocrinol 151(Suppl 1): S93-S101, 2004.
23. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25: 102-152, 2004.
24. Sze L, Schmid C, Bloch KE, Bernays R, Brändle M. Effect of transsphenoidal surgery on sleep apnoea in acromegaly. Eur J Endocrinol 156: 321-329, 2007.
25. Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB. Transsphenoidal microsurgery for growth hormonesecreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 83: 3411-3418, 1998.
26. Legrand V, Beckers A, Pham VT, Demoulin JC, Stevenaert A. Dramatic improvement of severe dilated cardiomyopathy in an acromegalic patient after treatment with octreotide and transsphenoidal surgery. Eur Heart J 15: 1286-1289, 1994.
27. MacCarthy P, Kearney M, Nolan J, et al. Prognosis in heart failure with preserved left ventricular systolic function: prospective cohort study. BMJ 327: 78-79, 2003.